TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel disease | Synapse
April 23, 2026
TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel disease
Puntos clave
This study investigates the role of TWSG1 genetic variation in predicting response to ustekinumab treatment in inflammatory bowel disease patients.
Assessed genetic variation in TWSG1 among patients treated with ustekinumab for inflammatory bowel disease.
Evaluated clinical remission rates in patients with and without TWSG1 SNV.
TWSG1 SNV is linked to higher rates of early and sustained clinical remission in patients using ustekinumab.
Wild-type carriers who did not achieve remission did not benefit from high-dose ustekinumab treatment.
Resumen
TWSG1 SNV was associated with early and persistent clinical remission in ustekinumab-exposed IBD patients. Wild-type carriers who did not achieve remission were not rescued with high-dose treatment.